Fujifilm announced today that it entered into an asset purchase agreement for the global digital pathology business of Inspirata.
Upon completing the agreement, Fujifilm absorbs Inspirata’s Dynamyx digital pathology technology. Additionally, it takes on employees and customers of the company. Fujifilm expects to complete the transaction in early 2023. Terms of the agreement have not been disclosed.
Inspirata received FDA clearance for the Dynamyx digital pathology software in March. Dynamyx allows for the use of whole slide images (WSIs) for primary diagnosis in place of traditional glass slides. The software includes an intuitive user interface with many annotation tools. It also features a universal viewer and customizable third-party AI applications to be made available as needed by pathologists.
Fujifilm said in a news release that the acquisition expands its Synapse enterprise imaging offering. It enables the integration of pathology images into a healthcare organization’s electronic health record system. This can help streamline care delivery for oncology patients and provider teams, Fujifilm said.
“Acquiring Inspirata’s digital pathology business allows Fujifilm to be an even stronger healthcare partner – bridging a technological gap between pathology, radiology and oncology to facilitate a more collaborative approach to care delivery across the enterprise,” said Teiichi Goto, president and CEO, representative director, Fujifilm. “We’re thrilled to welcome Inspirata’s digital pathology experts to Fujifilm’s growing medical informatics business, along with their renowned global customer base, as together we work to drive the digitization and advancement of healthcare.”
More on Dynamix and Inspirata
Dynamix, an open, vendor-agnostic, end-to-end digital pathology offering joins Fujifilm’s Synapse enterprising imaging portfolio. The system creates an easier path for more pathology labs to digitize patient results and utilize centralized imaging records.
The acquisition builds upon an established partnership between Fujifilm and Inspirata. In 2020, the companies entered into a commercial partnership to use the digital pathology platform. The partnership began with exclusivity in the United Kingdom, Italy, Spain, Portugal, Belgium, the Netherlands, and Luxembourg.
Fujifilm said the addition to its portfolio allows it to offer “one of the most comprehensive enterprise imaging portfolios on the market.” It also creates opportunities to support pharmaceutical and contract research organizations with toxicity testing data management.
“Since launching our European partnership with Inspirata three years ago, we’ve seen great success implementing our combined technologies in several healthcare organizations, notably in the UK,” said Masa Fukumoto, managing director, Fujifilm Healthcare Europe and SVP, Fujifilm Medical Systems Europe. “We’ve received feedback from customers anticipating digitizing pathology will be the most transformative thing they do for their practice, and we look forward to continuing our global expansion.”